Hengrui Strikes $500 Million Global Drug Deal with GSK Potential Payouts Up to $12 Billion
Jiangsu Hengrui Pharmaceuticals has signed a major licensing agreement, granting GlaxoSmithKline (GSK) worldwide rights to its HRS-9821 drug and 11 additional programs for an upfront payment of $500 million. If all development and sales milestones are reached, Hengrui could receive as much as $12 billion in total.
HRS-9821 is currently in development for chronic obstructive pulmonary disease (COPD), while the other assets span early-stage projects in oncology, respiratory, immunology, and inflammation. News of the deal sent Hengrui’s Shanghai-listed shares up 6.6% and its Hong Kong shares soaring 8.5%, far outperforming local indices.
This blockbuster partnership highlights the increasing global footprint of Chinese pharmaceutical innovation and brings Hengrui one step closer to international markets.
You May Interested In
SS-31 Cosmetic peptides, discounted price improving cognitive impairment factory supply
$8E+1/UNIT FOB
2026-09-10
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Evonik and AMSilk Expand Collaboration to Develop Sustainable Biotech Silk Materials
-
BASF and Clariant Exit Quietly! Behind Henkel’s High-Priced Acquisition, Why Did Former Allies Choose to “Let Go”?
-
INEOS Inovyn Moths Methyl Chlorocarbonate Production Facility in Tavaux, France
-
Beiersdorf Launches Eucerin Skincare Brand in Japan
-
Henkel's Acquisition of Stahl Enters Regulatory Countdown: Will the €2.1 Billion Deal Go Through?
-
The Pill That Could Swallow the Needle: Novo Nordisk Launches Oral Wegovy in U.S. Weight-Loss Revolution
-
From Desert Sands to Dining Tables: Arab Food & Beverage Sector Emerges as Investment Powerhouse
-
Korea’s Petrochemical Pivot: Industry Embraces Historic Restructuring to Slash Overcapacity
-
Dafeng Haijianuo’s RMB 246 Million Technical Revamp Project Takes Shape, with Multiple Production Lines for Vitamin K1, Folic Acid, and Others Under Construction
-
LANXESS Expands Rubber Additives Production at Qingdao Plant
Recommend Reading
-
![Hormuz Crisis Pushes Up Urea Prices as Yara’s Quarterly EBITDA Jumps 39%]()
Hormuz Crisis Pushes Up Urea Prices as Yara’s Quarterly EBITDA Jumps 39%
-
![Ingredion Agrees to Acquire Tate & Lyle for $3.6 Billion, Reshaping the Global Specialty Ingredients Market]()
Ingredion Agrees to Acquire Tate & Lyle for $3.6 Billion, Reshaping the Global Specialty Ingredients Market
-
![Wanhua Chemical and Xingfa Group Jointly Develop 5.32 Billion Yuan Phosphate Mine]()
Wanhua Chemical and Xingfa Group Jointly Develop 5.32 Billion Yuan Phosphate Mine
-
![BASF, Covestro, Huntsman Raise MDI Prices in North America Amid Global Supply Crunch]()
BASF, Covestro, Huntsman Raise MDI Prices in North America Amid Global Supply Crunch
-
![AstraZeneca Pays Up to $1.5 Billion for Global Rights to Chinese Lung Cancer Drug]()
AstraZeneca Pays Up to $1.5 Billion for Global Rights to Chinese Lung Cancer Drug
-
![China’s Marine Fuel Market in May Experiences Volatile Downward Trends]()
China’s Marine Fuel Market in May Experiences Volatile Downward Trends
-
![Escalation of Conflict in the Middle East Drives Oil Prices Above $110; Supply Concerns Continue to Intensify]()
Escalation of Conflict in the Middle East Drives Oil Prices Above $110; Supply Concerns Continue to Intensify
-
![May ethyl acetate market continues to decline in China]()
May ethyl acetate market continues to decline in China
-
![May Acetic Acid Market Shakes and Declines]()
May Acetic Acid Market Shakes and Declines
-
![Sodium Nitrate: Fertilizer, Food Curing, and Explosive History]()
Sodium Nitrate: Fertilizer, Food Curing, and Explosive History
